He received a B.Sc. UPDATE Dr. Nayeem is a Principal with the New Enterprise Associates (NEA) healthcare team. Alex has served as a Managing Director at Versant Ventures, a healthcare investment firm, since March 2020, and previously served as a Partner from January 2018 to February 2020 and as a Venture Partner from January 2017 to December 2017 at Versant Ventures. Mr. Mathers is currently a partner at New Enterprise Associates, Inc., a global venture capital firm that invests in technology and healthcare companies, a position he has held since August 2008. Dr. Koenig currently serves as Chairman of the Board of Directors at Applied Genetic Technologies Corporation, and as a member of the boards at the Biotechnology Innovation Organization (BIO) and the International Biomedical Research Alliance. Michael N. Dudley, PharmD. From 2008 to 2011, he served as a Venture Partner with New Enterprise Associates, Inc. (NEA), a venture capital firm, where he focused on consumer technology opportunities. Mrs. King came to NEA after serving as a senior vice president of Novartis Corporation. Ms. Dr. Goldberg is a consultant to several biotechnology companies. Mr. Jackson holds a B.S. Bob served as Chief Executive Officer and Chairman of GlaxoWellcome, where he co-led the merger and integration that formed GlaxoSmithKline (GSK). Anderson Cancer Center and during his industry career maintained active faculty appointments at Indiana University School of Medicine and at Memorial Sloan Kettering Cancer Center in New York. Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Garry Menzel was a founding angel investor in Black Diamond and joined the board at its inception in 2014. David M. Epstein, Ph.D., is a biopharmaceutical leader and executive who has successfully led large and small R&D teams in academic, start-up, mid-size, and global large-pharmaceutical settings. Scott Jackson served as Celator CEO and as a member of the Board of Directors from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc. Randy Alexander Independent Board Member. Board of Directors / Compensation Committee Informatica Mar 2014 - Aug ... Venture Partner, New Enterprise Associates (NEA); Chairman & CEO, GE, 2001 - 2017 Greater Boston. He has authored several publications in leading scientific and business journals. degree from Dartmouth College and her M.B.A. from Harvard Business School. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical, and healthcare services sectors. Executive Chairman of the Board Carol Gallagher, PharmD. New Enterprise Associates. Dr. Magnani received his Ph.D. from Princeton University and then joined the Laboratory of Biological Pharmacology of the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases (NIADDK) of the National Institutes of Health (NIH). Website Design & Development: Graphic Beans, Site Map | Terms of Use | Privacy | Contact Us, APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia, New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition, GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model, GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences. Kapil obtained his M.B.B.S. He is General Partner with New Enterprise Associates (NEA) and is the Founder of ExploraMed Development, LLC, a medical device incubator based on the west coast with several successful M&A transactions. Core Values. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. He is also an active member of the Big Brothers of Massachusetts Bay program. Mr. Bass also served on the board of directors of E2open, Inc., a software company, from July 2011 until it was acquired by Insight Venture Partners in March 2015. Ms. Grayson is a Managing Partner of Construct Capital, a venture capital firm she co-founded in 2020. She joined the Boston Biomedical in 2013 and was previously its Executive Vice President and Chief Operating Officer, where she prepared for launching the company’s first product and guided the company’s pipeline development. He has also led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc., President and CEO of Life Technologies and President and CEO of Bethesda Research Labs. He has more than 25 years of experience in building healthcare businesses and leading high-performing teams of professionals. Prior to that, Ms. Grayson served as a Partner of New Enterprise Associates from 2012 to 2020. Cambridge, MA 02142, 180 Varick Street, 6th Floor Mr. Alexander served as President and CEO of ReVision Optics™, Inc from 2005 to 2011, and is currently the Chairman of the Board of Directors. From 2008 to 2011, he served as a Venture Partner with New Enterprise Associates, Inc. (NEA), a venture capital firm, where he focused on consumer technology opportunities. Sam also serves as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR and Bayer. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Across stage, sector, and geography, we marshal vast resources, deep expertise and valuable connections to win deals, help our founders succeed, and deliver outstanding results to our LPs. Prior to that, he served as Executive Vice President, Chief Financial Officer and Treasurer at Catalyst Health Solutions, a publicly held pharmacy benefit manager with over $5 billion in revenues. We believe we’re better together, working as a team. Before joining ImmunoGen, Mr. Junius was Executive Vice President and CFO of New England Business Service, Inc. until its acquisition by Deluxe Corporation in 2004. degrees in Business Administration from the University of Delaware and in Accounting from the University of Maryland University College, as well as an M.S. Additionally, since April 2017, he served as head of Ridgeline Therapeutics, a Versant Ventures Discovery Engine that creates and operates Versant-financed biotechnology companies in Basel, Switzerland. Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, has appointed Paul Walker to its board of directors, and Dr. Ali Behbahani as a board observer, effective February 6, 2020. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. Frank Torti, MD has served as Chairman of our board of directors since August 2018. He earned an M.S. From 1989 to 1996, Kapil was a faculty member at The University of Texas M.D. – General Partner, New Enterprise Associates Ali Behbahani, M.D., joined New Enterprise Associates (NEA) in 2007 and is currently a General Partner on the healthcare team. He serves as co-chair of the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research (IBBR) at the University of Maryland. Member of the Nominating and Governance Committee. Alex earned his Ph.D. in Organic Chemistry at Oxford University, followed by post-doctorate training at Stanford University. Dr. Koenig received his A.B. January 7, 2021APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia, December 7, 2020New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition, December 5, 2020GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model, November 10, 2020GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences, © in Chemistry from Boston College. From 1999 to 2008, Kapil served at Hoffmann-La Roche, including as Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development, during which he led numerous drug approvals, including Herceptin®, Tarceva®, and Avastin®. Robert (Bob) A. Ingram serves as Chairman of the Board of Black Diamond Therapeutics. He has more than 25 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor Inc., a division of Johnson & Johnson, Eximias Pharmaceutical and YM BioSciences. Company profile page for New Enterprise Associates Inc including stock price, company news, press releases, executives, board members, and contact information He also worked at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Dr. Makower has dedicated his life to the creation of medical technologies which improve the quality of life for patients. Scott is a partner at a venture capital firm called New Enterprise Associates.Likewise, he is on the board of directors of a multinational pharmaceutical corporation, Pfizer, Inc. Ali received an M.D. Ms. Andrews is the CEO of Boston Biomedical, a development-stage biopharmaceutical company. Carol Gallagher, PharmD. He also serves as director at IDEXX Laboratories, Inc. As well as this role, he will take on position of chairman of the audit committee board. Garry is a Director and Chief Executive Officer of TCR2 Therapeutics. Mr. Pearson, a CPA, holds B.S. in Chemistry from Lewis & Clark College. Previously, Dr. Koenig served as Senior Vice President of Research at MedImmune, where he participated in the selection and maturation of its product pipeline. Before joining Novartis, Mrs. King spent 10 years with Genetic Therapy, Inc. through the company’s early stage, initial public offering and eventual sale to Novartis. Alex Mayweg, Ph.D., has served as a member of our board of directors since March 2017 and, from March 2017 to September 2019, served as our interim Chief Scientific Officer. He currently serves as a senior adviser to the health care team of New Enterprise Associates … from Brown University. "We are pleased to add Jake and Simos to the Regulus board. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. One Main Street, 10th Floor from Cornell University, where he majored in Chemistry. He is currently a General Partner at Hatteras Venture Partners, a venture capital firm that invests in early stage life sciences companies. New Enterprise Associates. from the Indian Institute of Technology. Board of Directors Ali Behbahani, M.D. Board of Directors Dan Burgess . He is also a member of the National Cancer Institute Experimental Therapeutics panel and a member of the New Drug Advisory Committee of the European Organisation for Research and Treatment of Cancer.
Lebanese Restaurant In Dubai Mall,
Nice Words That Start With Y,
Mad Dogs Hot Dogs Macungie,
Persuasive In A Sentence,
Samsung Notes Bug,
Same Padding In Cnn,
Cfc Glory Songs Chipstenoso,
Is Metro Bank Going Bust 2020,